GSK plc (NYSE:GSK) has failed to meet key ethical and regulatory standards in how it marketed and provided prescribing ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ...

GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled. Spokespeople for the companies did not immediately respond to requests for ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. The post Were we right to ditch our GSK ...